Float Short %

Margin Of Safety %

Put/Call OI Ratio

0.25

EPS Next Q Diff

0.09

EPS Last/This Y

-0.08

EPS This/Next Y

0.08

Price

1.76

Target Price

4.23

Analyst Recom

Performance Q

9.38

Relative Volume

1.56

Beta

0.26

Ticker: OVID

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	OVID	1.765	0.03	1.41	11581
2025-12-29	OVID	1.65	0.04	0.00	11737
2025-12-30	OVID	1.62	0.04	0.00	11667
2025-12-31	OVID	1.63	0.05	0.06	11224
2026-01-02	OVID	1.76	0.05	0.59	11234
2026-01-05	OVID	1.66	0.05	0.00	11227
2026-01-06	OVID	1.765	0.05	0.00	11073
2026-01-07	OVID	1.79	0.05	0.30	11083
2026-01-08	OVID	1.735	0.05	0.00	11124
2026-01-09	OVID	1.675	0.05	2.18	11243
2026-01-12	OVID	1.615	0.05	32.50	11267
2026-01-13	OVID	1.645	0.07	0.43	11385
2026-01-14	OVID	1.65	0.07	0.04	11396
2026-01-15	OVID	1.6	0.07	0.00	11422
2026-01-16	OVID	1.575	0.07	0.26	11331
2026-01-20	OVID	1.525	0.25	0.17	3127
2026-01-21	OVID	1.65	0.25	0.01	3311
2026-01-22	OVID	1.755	0.25	0.00	3346
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	OVID	1.76	24.4	-15.5	-0.45
2025-12-29	OVID	1.64	24.4	-11.4	-0.45
2025-12-30	OVID	1.62	24.4	-15.2	-0.45
2025-12-31	OVID	1.62	24.4	-16.2	-0.45
2026-01-02	OVID	1.75	24.4	-21.4	-0.45
2026-01-05	OVID	1.66	24.4	-13.0	-0.45
2026-01-06	OVID	1.76	24.4	-20.5	-0.45
2026-01-07	OVID	1.79	24.4	-17.5	-0.45
2026-01-08	OVID	1.74	24.4	-14.6	-0.45
2026-01-09	OVID	1.67	24.4	-14.3	-0.45
2026-01-12	OVID	1.62	24.4	-14.0	-0.45
2026-01-13	OVID	1.65	24.4	-17.8	-0.45
2026-01-14	OVID	1.64	24.4	-15.9	-0.45
2026-01-15	OVID	1.60	24.4	-14.4	-0.45
2026-01-16	OVID	1.57	24.4	-15.7	-0.45
2026-01-20	OVID	1.52	24.4	-14.3	-0.45
2026-01-21	OVID	1.65	24.4	-21.9	-0.45
2026-01-22	OVID	1.76	24.4	-20.5	-0.45
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	OVID	0.00	-6.48	7.16
2025-12-29	OVID	0.00	-1.44	7.16
2025-12-30	OVID	0.00	-1.44	7.16
2025-12-31	OVID	0.00	-1.44	7.16
2026-01-02	OVID	0.00	-1.44	7.16
2026-01-05	OVID	0.00	-1.43	7.16
2026-01-06	OVID	0.00	-1.43	7.16
2026-01-07	OVID	0.00	-1.43	7.16
2026-01-08	OVID	0.00	-1.43	7.16
2026-01-09	OVID	0.00	-1.43	7.16
2026-01-12	OVID	0.00	1.77	7.16
2026-01-13	OVID	0.00	1.77	7.52
2026-01-14	OVID	0.00	1.77	7.52
2026-01-15	OVID	0.00	1.77	7.52
2026-01-16	OVID	0.00	1.77	7.52
2026-01-20	OVID	0.00	8.48	7.52
2026-01-21	OVID	0.00	8.48	7.52
2026-01-22	OVID	0.00	8.48	0
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

-0.17

Avg. EPS Est. Current Quarter

-0.1

Avg. EPS Est. Next Quarter

-0.08

Insider Transactions

Institutional Transactions

8.48

Beta

0.26

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

63.3

Max Drawdown 5-Year %

-94.3

Target Price

4.23

P/E

Forward P/E

PEG

P/S

34.47

P/B

2.79

P/Free Cash Flow

EPS

-0.51

Average EPS Est. Cur. Y

-0.45

EPS Next Y. (Est.)

-0.37

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-549.62

Relative Volume

1.56

Return on Equity vs Sector %

-108.5

Return on Equity vs Industry %

-92.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

-20.5

Ovid Therapeutics Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 23

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

stock quote shares OVID – Ovid Therapeutics Inc. Stock Price stock today

news today OVID – Ovid Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch OVID – Ovid Therapeutics Inc. yahoo finance google finance

stock history OVID – Ovid Therapeutics Inc. invest stock market

stock prices OVID premarket after hours

ticker OVID fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: OVID

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y